Millipore Corporation and Applikon Biotechnology have announced an agreement to co-develop and distribute disposable bioreactor systems for biopharmaceutical applications.
'Our collaboration with Applikon Biotechnology will close an important gap in our disposable product offering and strengthens our position in upstream process development,' said Andrew Bulpin, vice president of Millipore's Upstream Processing business unit.
'Applikon and Millipore have a shared vision for the promise of disposable bioreactor systems and we shall integrate such systems across the spectrum of biopharmaceutical companies,' said Arthur Oudshoorn, managing director of Applikon Biotechnology.
